score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	AR	Amplification				0.0	0.0		Putatively Actionable	Abiraterone	Hormone therapy	Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf	Putatively Actionable	Abiraterone	Hormone therapy	Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf						0				AR Amplification		PROS12319B-SU2C-06115121	PROS12319B-SU2C-06115121-Tumor-SM-4W2NG	
Putatively Actionable			Clinical evidence	Copy Number	RB1	Deletion				0.0	0.0														Putatively Actionable	0.0	Deletion of chromosome 13 seems to have an amplifying effect on cell cycle gene expression and is reported to be associated with short event-free survival (EFS) and overall survival (OS). This copy loss event results in haploinsufficiency of RB1 and other genes mapped to chromosome 13.	National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf	0				RB1 Deletion		PROS12319B-SU2C-06115121	PROS12319B-SU2C-06115121-Tumor-SM-4W2NG	
Investigate Actionability - High		Clinical evidence	Clinical evidence	Somatic Variant	TP53	Missense	p.C176F	0.9175	97.0	0.0	0.0								Investigate Actionability - Low	Lenalidomide	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability - High	0.0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	3.0	1.0	0.0	TP53 p.C176F (Missense)		PROS12319B-SU2C-06115121	PROS12319B-SU2C-06115121-Tumor-SM-4W2NG	PROS12319B-SU2C-06115121-Normal-SM-4W2NZ
Investigate Actionability - High			Inferential	Aneuploidy	Whole genome doubling																				Investigate Actionability - High	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						PROS12319B-SU2C-06115121		
Investigate Actionability - Low		Clinical evidence		Copy Number	CRKL	Deletion				0.0	0.0								Investigate Actionability - Low	Getfitinib	Targeted therapy	CRKL amplification was observed in an EGFR inhibitor resistant tumor after researchers observed that cells from gefitinib-sensitive cell line (HCC827) overexpressing CRKL became resistant to gefitinib relative to controls.	Cheung HW, Du J, Boehm JS, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011;1(7):608-25.	https://doi.org/10.1158/2159-8290.CD-11-0046						0				CRKL Deletion		PROS12319B-SU2C-06115121	PROS12319B-SU2C-06115121-Tumor-SM-4W2NG	
Biologically Relevant				Copy Number	EZH2	Deletion				0.0	0.0																			0				EZH2 Deletion		PROS12319B-SU2C-06115121	PROS12319B-SU2C-06115121-Tumor-SM-4W2NG	
Biologically Relevant				Copy Number	BCR	Deletion				0.0	0.0																			0				BCR Deletion		PROS12319B-SU2C-06115121	PROS12319B-SU2C-06115121-Tumor-SM-4W2NG	
Biologically Relevant				Copy Number	MAPK1	Deletion				0.0	0.0																			0				MAPK1 Deletion		PROS12319B-SU2C-06115121	PROS12319B-SU2C-06115121-Tumor-SM-4W2NG	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																							0				Supporting variants: PRDM2 p.703_704insP (Insertion)		PROS12319B-SU2C-06115121		
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.501																							0				COSMIC Signature 1 (50%)		PROS12319B-SU2C-06115121		
